Related references
Note: Only part of the references are listed.Characterization and Specification of a Trivalent Protein-Based Pneumococcal Vaccine Formulation Using an Adjuvant-Free Nanogel Nasal Delivery System
Yoshikazu Yuki et al.
MOLECULAR PHARMACEUTICS (2021)
Complement evasion by the human respiratory tract pathogensHaemophilus influenzaeandMoraxella catarrhalis
Kristian Riesbeck
FEBS LETTERS (2020)
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
Almea Matanock et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
The Role of Serotype-Specific Immunological Memory in Pneumococcal Vaccination: Current Knowledge and Future Prospects
Ioanna Papadatou et al.
VACCINES (2019)
Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults
Fawziah Marra et al.
AGING AND DISEASE (2019)
Transcutaneous immunization with pneumococcal surface protein A in mice
Hiromi Nagano et al.
LARYNGOSCOPE (2018)
The diversity of the proline-rich domain of pneumococcal surface protein A (PspA): Potential relevance to a broad-spectrum vaccine
Reshmi Mukerji et al.
VACCINE (2018)
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
Pauline A. Waight et al.
LANCET INFECTIOUS DISEASES (2015)
Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques
Y. Fukuyama et al.
MUCOSAL IMMUNOLOGY (2015)
Mapping of Epitopes Recognized by Antibodies Induced by Immunization of Mice with PspA and PspC
Cintia F. M. Vadesilho et al.
CLINICAL AND VACCINE IMMUNOLOGY (2014)
IgG subclasses and allotypes: from structure to effector functions
Gestur Vidarsson et al.
FRONTIERS IN IMMUNOLOGY (2014)
Modified Opsonization, Phagocytosis, and Killing Assays To Measure Potentially Protective Antibodies against Pneumococcal Surface Protein A
Calvin C. Daniels et al.
CLINICAL AND VACCINE IMMUNOLOGY (2013)
Nanogel-Based PspA Intranasal Vaccine Prevents Invasive Disease and Nasal Colonization by Streptococcus pneumoniae
Il Gyu Kong et al.
INFECTION AND IMMUNITY (2013)
Population genomics of post-vaccine changes in pneumococcal epidemiology
Nicholas J. Croucher et al.
NATURE GENETICS (2013)
A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA)
Kristopher R. Genschmer et al.
VACCINE (2013)
The Absence of PspA or Presence of Antibody to PspA Facilitates the Complement-Dependent Phagocytosis of Pneumococci In Vitro
Bing Ren et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells
Elizabeth A. Clutterbuck et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Intranasal Vaccination with Chitosan-DNA Nanoparticles Expressing Pneumococcal Surface Antigen A Protects Mice against Nasopharyngeal Colonization by Streptococcus pneumoniae
Jianghong Xu et al.
CLINICAL AND VACCINE IMMUNOLOGY (2011)
The Proline-Rich Region of Pneumococcal Surface Proteins A and C Contains Surface-Accessible Epitopes Common to All Pneumococci and Elicits Antibody-Mediated Protection against Sepsis
Calvin C. Daniels et al.
INFECTION AND IMMUNITY (2010)
In Vivo Molecular Imaging Analysis of a Nasal Vaccine That Induces Protective Immunity against Botulism in Nonhuman Primates
Yoshikazu Yuki et al.
JOURNAL OF IMMUNOLOGY (2010)
Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines
Tomonori Nochi et al.
NATURE MATERIALS (2010)
Self-assembled cationic nanogels for intracellular protein delivery
Hirohito Ayame et al.
BIOCONJUGATE CHEMISTRY (2008)
Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae
Martina M. Ochs et al.
MICROBIAL PATHOGENESIS (2008)
Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A
Maria Leonor Sarno Oliveira et al.
MICROBES AND INFECTION (2006)
Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries
SK Hollingshead et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2006)
Mucosal immunity and vaccines
J Holmgren et al.
NATURE MEDICINE (2005)
Streptococcus pneumoniae colonisation:: the key to pneumococcal disease
D Bogaert et al.
LANCET INFECTIOUS DISEASES (2004)
Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland
M Mutsch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Nalt- versus Peyer's-patch-mediated mucosal immunity
H Kiyono et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface
B Ren et al.
INFECTION AND IMMUNITY (2004)
Microarray analysis of pneumococcal gene expression during invasive disease
CJ Orihuela et al.
INFECTION AND IMMUNITY (2004)
Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues
FW van Ginkel et al.
JOURNAL OF IMMUNOLOGY (2000)
Diversity of PspA:: Mosaic genes and evidence for past recombination in Streptococcus pneumoniae
SK Hollingshead et al.
INFECTION AND IMMUNITY (2000)
Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules
GS Nabors et al.
VACCINE (2000)
Share Paper
